Progenity Stock

Progenity Equity

Delisted

The The Equity of Progenity (PROG) as of Aug 15, 2026 is -84.98 M USD. In the previous year, The Equity was -106.99 M USD — a change of -20.58% (higher).

Equity

-84.98 MUSD

YoY

-20.58%

Last updated:

In 2026, Progenity's equity was -84.98 M USD, a -20.58% increase from the -106.99 M USD equity in the previous year.

Access this data via the Eulerpool API

Progenity Stock analysis

What does Progenity do? Progenity Inc. is an American company specializing in the development and marketing of diagnostic tests and genetic screening solutions. It was founded in 2012 and is headquartered in San Diego, California. Progenity is a leading provider of prenatal screening and diagnostic solutions. The company offers a wide range of tests that help expectant parents identify potential health risks for their unborn child. Progenity's prenatal screening palette includes tests for determining chromosomal abnormalities, genetic disorders, and other health risks. A major advantage of these tests is that they are non-invasive, meaning that no dangerous invasive procedures need to be performed. Another important division of Progenity focuses on gastrointestinal health, where the company offers various diagnostic tests to identify and treat gastrointestinal diseases early. This includes tests for detecting colon cancer as well as genetic tests that indicate an increased risk for familial colon cancer syndromes. Progenity also has a division that focuses on cardiovascular diseases. Here, they offer genetic tests, among other things, to determine the risk of heart disease. In addition, the company offers a wide range of diagnostic solutions for general health, such as tests for identifying infectious diseases like HIV or HPV. Progenity also offers its customers various screening and diagnostic tests tailored to specific target groups. This includes tests for women seeking fertility treatment, as well as tests aiming to identify specific hereditary diseases related to cancer or other conditions. To provide customers with the best possible solutions, Progenity utilizes state-of-the-art technologies and innovative methods. The company is a leader in the application of liquid biopsy tests, an innovative method for identifying cancer cells in the blood. For a long time, Progenity has worked closely with leading US health authorities and is accredited by CLIA, the Clinical Laboratory Improvement Amendments. This means that the company operates in accordance with established standards and best practices and can provide its customers with accurate and reliable diagnostic solutions. In recent years, Progenity has experienced an impressive growth rate and has become a recognized provider of diagnostic solutions with a wide range of tests covering various areas of health. The company is committed to providing customers with the best possible solutions to promote their health and well-being. Progenity is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Progenity's Equity

Progenity's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Progenity's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Progenity's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Progenity's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Progenity’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Progenity stock

The Equity of Progenity is -84.98 M USD in 2026.

The Equity of Progenity changed from -106.99 M USD to -84.98 M USD, representing a -20.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Progenity since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Progenity historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Progenity

All Key Metrics — Progenity